Organic compounds

Patent metadata

Field	Value
Publication number	US-11773095-B2
Application number	US-202217813473-A
Country	US
Kind code	B2
Filing date	Jul 19, 2022
Priority date	Jul 26, 2017
Publication date	Oct 3, 2023
Grant date	Oct 3, 2023

Abstract

The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.

First claim

What is claimed:

1. A method for the treatment of a central nervous system disorder, comprising administering to a patient in need thereof a compound of a Formula I:

wherein:
R 5 is —C(O)—O—C(R a )(R b )(R c ), —C(O)—O—CH 2 —O—C(R a )(R b )(R c ) or —C(R 6 )(R 7 )—O—C(O)—R 8 :
Z is O, or —C(O)—;
R 8 is —C(R a )(R b )(R c ), —O—C(R a )(R b )(R c ), or —N(R d )(R e );
R a , R b and R c are each independently selected from H and C 1-24 alkyl;
R d and R e are each independently selected from H and C 1-24 alkyl;
R 6 and R 7 are each independently selected from H, C 1-6 alkyl, carboxy and C 1-6 alkoxycarbonyl;
in free or pharmaceutically acceptable salt form;

or
a compound of a Formula II:

wherein:
Z is O, or —C(O)—;
R 1 , R 2 , R 3 and R 4 are each independently selected from H and C 1-6 alkyl;
n is an integer from 1 to 23;
in free or pharmaceutically acceptable salt form;
wherein said disorder is selected from the group consisting of anxiety, general anxiety disorder, social anxiety disorder, depression, refractory depression, major depressive disorder, treatment-resistant depression, psychosis, schizophrenia, sleep disorders, migraine, pain, cephalic pain, idiopathic pain, neuropathic pain, chronic pain, fibromyalgia, chronic fatigue, gastrointestinal disorders, mood disorders, drug dependencies, opiate dependency, cocaine dependency, amphetamine dependency, alcohol dependency, withdrawal from drug or alcohol dependency, opiate overdose, binge eating disorder, obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), compulsive gambling disorder, compulsive eating disorder, body dysmorphic disorder, pathological grooming disorder, and combinations thereof.

2. The method according to claim 1 , wherein said disorder is selected from the group consisting of depression, refractory depression, major depressive disorder, treatment-resistant depression, mood disorders and combination thereof.

3. The method according to claim 1 , wherein said disorder is a disorder selected from the group consisting of psychosis, schizophrenia, sleep disorders, and combinations thereof.

4. The method according to claim 1 , wherein said disorder is a disorder selected from the following: (i) psychosis in a patient suffering from depression; (2) depression in a patient suffering from psychosis; (3) mood disorders in a patient with psychosis; (4) sleep disorders in a patient with psychosis; and (5) substance addiction, substance use disorders and/or substance-induced disorders.

5. The method according to claim 1 , wherein said disorder is a disorder selected from obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), general anxiety disorder, social anxiety disorder, and combination thereof.

6. The method according to claim 1 , wherein said disorder is a disorder selected from pain, cephalic pain, idiopathic pain, neuropathic pain, chronic pain, fibromyalgia, chronic fatigue, opiate dependency, cocaine dependency, amphetamine dependency, alcohol dependency, withdrawal from drug or alcohol dependency, and opiate overdose.

7. The method according to claim 1 , wherein the method further comprises administration of an agonist or partial agonist, or inverse agonist or antagonist, of the mu-opiate, kappa-opiate, delta-opiate, and/or nociceptin/orphanin receptors.

8. The method according to claim 1 , wherein the method further comprises administration of buprenorphine, methadone, naloxone or naltrexone.

9. The method according to claim 1 , wherein the method comprises administering the compound of Formula I.

10. The method according to claim 9 , wherein, in the compound of Formula I, Z is O.

11. The method according to claim 9 , wherein, in the compound of Formula I, Z is —C(O).

12. The method according to claim 9 , wherein, in the compound of Formula I, R 5 is —C(O)—O—C(R a )(R b )(R c ).

13. The method according to claim 9 , wherein, in the compound of Formula I, R 5 is —C(O)—O—CH 2 —O—C(R a )(R b )(R c ).

14. The method according to claim 9 , wherein, in the compound of Formula I, R 5 is —C(R 6 )(R 7 )—O—C(O)—R 8 , and R 8 is —C(R a )(R b )(R c ).

15. The method according to claim 9 , wherein, in the compound of Formula I, R 5 is —C(R 6 )(R 7 )—O—C(O)—R 8 , and R 8 is —O—C(R a )(R b )(R c ).

16. The method according to claim 9 , wherein, in the compound of Formula I, R 5 is —C(R 6 )(R 7 )—O—C(O)—R 8 , and R 8 is —N(R d )(R e ).

17. The method according to claim 9 , wherein the compound of Formula I is in the form of a pharmaceutically acceptable salt.

18. The method according to claim 1 , wherein the method comprises administering the compound of Formula II.

19. The method according to claim 18 , wherein the compound of Formula II is in the form of a pharmaceutically acceptable salt.

20. The method according to claim 1 , wherein the method comprises administering the compound of Formula I or the compound of Formula II in the form of a pharmaceutical composition comprising the compound of Formula I or the compound of Formula II in free or pharmaceutically acceptable salt form, in admixture with a pharmaceutically acceptable diluent or carrier, and wherein the composition is formulated as a long acting injectable.

21. The method according to claim 20 , wherein the long acting injectable is a subcutaneous or intramuscular injection.

Assignees

• Intra Cellular Therapies Inc

Inventors

• Li Peng
• Zheng Hailin
• Davis Robert
• Mates Sharon
• Vanover Kimberly
• Snyder Gretchen

Classifications

• C07D471/16 Primary

  Peri-condensed systems · CPC title

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P25/36

  Opioid-abuse · CPC title